

## Publicaciones en revistas científicas del grupo de investigación en infecciones respiratorias agudas del Centro Nacional de Epidemiología del Instituto de Salud Carlos III

Publicaciones por año, desde 2010, actualizado a 20 de septiembre de 2024

### Año 2024

1. Zeitlin J, Philibert M, Barros H, Broeders L, Cap J, Draušnik Ž, et al. Socioeconomic disparities in changes to preterm birth and stillbirth rates during the first year of the COVID-19 pandemic: a study of 21 European countries. *Eur J Public Health*. 2024 Jul 1;34(Supplement\_1):i58–66.
2. Young JJ, Mutch H, Rose AMC, Evans JMM. Enhanced surveillance of hospitalized COVID-19 patients in Europe: an evaluation of the I-MOVE-COVID-19 surveillance network. *Eur J Public Health*. 2024 Feb 5;34(1):181–9.
3. Varea-Jiménez E, Aznar Cano E, Vega-Piris L, Martínez Sánchez EV, Mazagatos C, García San Miguel Rodríguez-Alarcón L, et al. Comparative severity of COVID-19 cases caused by Alpha, Delta or Omicron SARS-CoV-2 variants and its association with vaccination. *Enfermedades Infecc Microbiol Clin Engl Ed*. 2024 Apr;42(4):187–94.
4. Rose AMC, Pozo F, Martínez-Baz I, Mazagatos C, Bossuyt N, Cauchi JP, et al. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. *Influenza Other Respir Viruses*. 2024 Feb;18(2):e13255.
5. Monge S, Humphreys J, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Effectiveness of XBB.1.5 Monovalent COVID-19 Vaccines During a Period of XBB.1.5 Dominance in EU/EEA Countries, October to November 2023: A VEBIS-EHR Network Study. *Influenza Other Respir Viruses*. 2024 Apr;18(4):e13292.
6. Mazagatos C, Mendioroz J, Rumayor MB, Gallardo García V, Álvarez Río V, Cebollada Gracia AD, et al. Estimated Impact of Nirsevimab on the Incidence of Respiratory Syncytial Virus Infections Requiring Hospital Admission in Children < 1 Year, Weeks 40, 2023, to 8, 2024, Spain. *Influenza Other Respir Viruses*. 2024 May;18(5):e13294.
7. Maurel M, Mazagatos C, Goerlitz L, Oroszi B, Hooiveld M, Machado A, et al. Exploring the effect of clinical case definitions on influenza vaccine effectiveness estimation at primary care level: Results from the end-of-season 2022-23 VEBIS multicentre study in Europe. *Vaccine*. 2024 Jun 11;42(16):3547–54.
8. Maurel M, Howard J, Kissling E, Pozo F, Pérez-Gimeno G, Buda S, et al. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2024 Feb;29(8).

9. Laniece Delaunay C, Melo A, Maurel M, Mazagatos C, Goerlitz L, O'Donnell J, et al. Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024. *Vaccine*. 2024 Jul 25;42(19):3931–7.
10. Laniece Delaunay C, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, et al. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans. *JAMA Netw Open*. 2024 Jul 1;7(7):e2419258.
11. Lanièce Delaunay C, Martínez-Baz I, Sève N, Domegan L, Mazagatos C, Buda S, et al. COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2024 Mar;29(13).
12. Fontán-Vela M, Kissling E, Nicolay N, Braeye T, Van Evercooren I, Holm Hansen C, et al. Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged  $\geq 65$  years: results from a VEBIS network, Europe, October 2021 to July 2023. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2024 Jan;29(1).
13. Fontán-Vela M, Hernando V, Olmedo C, Coma E, Martínez M, Moreno-Perez D, et al. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2024 Feb 17;78(2):476–83.
14. Antunes L, Mazagatos C, Martínez-Baz I, Gomez V, Borg ML, Petrović G, et al. Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged  $\geq 60$  years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2024 Jan;29(3).

## Año 2023

15. Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Baruch J, et al. Vaccine effectiveness against COVID-19 hospitalisation in adults ( $\geq 20$  years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2023 Nov;28(47).
16. Rose AM, Nicolay N, Sandonis Martín V, Mazagatos C, Petrović G, Niessen FA, et al. Vaccine effectiveness against COVID-19 hospitalisation in adults ( $\geq 20$  years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2023 Nov;28(47).
17. Portillo-Van Diest A, Vilagut G, Alayo I, Ferrer M, Amigo F, Amann BL, et al. Traumatic stress symptoms among Spanish healthcare workers during the COVID-19 pandemic: a prospective study. *Epidemiol Psychiatr Sci*. 2023 Aug 9;32:e50.
18. Monge S, Rojas-Benedicto A, Olmedo C, Martín-Merino E, Mazagatos C, Limia A, et al. Effectiveness of a Second Dose of an mRNA Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in Individuals Previously Infected by Other Variants. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2023 Feb 8;76(3):e367–74.
19. Monge S, Pastor-Barriuso R, Hernán MA. The imprinting effect of covid-19 vaccines: an expected selection bias in observational studies. *BMJ*. 2023 Jun 7;381:e074404.

20. Monge S, Latasa Zamalloa P, Sierra Moros MJ, Pérez Olaso O, García San Miguel L, Varela C, et al. Lifting COVID-19 mitigation measures in Spain (May-June 2020). *Enferm Infecc Microbiol Clin*. 2023 Jan;41(1):11–7.
21. Meslé MMI, Sinnathamby M, Mook P, Pebody R, Lakhani A, Zambon M, et al. Seasonal and inter-seasonal RSV activity in the European Region during the COVID-19 pandemic from autumn 2020 to summer 2022. *Influenza Other Respir Viruses*. 2023 Nov;17(11):e13219.
22. Kissling E, Pozo F, Martínez-Baz I, Buda S, Vilcu AM, Domegan L, et al. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021-2022 I-MOVE primary care multicentre study. *Influenza Other Respir Viruses*. 2023 Jan;17(1):e13069.
23. Kissling E, Maurel M, Emborg HD, Whitaker H, McMenamin J, Howard J, et al. Interim 2022/23 influenza vaccine effectiveness: six European studies, October 2022 to January 2023. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2023 May;28(21).
24. Kislaya I, Sentís A, Starrfelt J, Nunes B, Martínez-Baz I, Nielsen KF, et al. Monitoring COVID-19 vaccine effectiveness against COVID-19 hospitalisation and death using electronic health registries in  $\geq 65$  years old population in six European countries, October 2021 to November 2022. *Influenza Other Respir Viruses*. 2023 Nov;17(11):e13195.
25. Hernán MA, Monge S. Selection bias due to conditioning on a collider. *BMJ*. 2023 Jun 7;381:1135.
26. Canelas-Fernández J, Mazagatos C, Delgado-Sanz C, Larrauri A. Influenza hospitalisations in Spain between the last influenza and COVID-19 pandemic (2009-2019). *Epidemiol Infect*. 2023 Oct 4;151:e177.
27. Barbeito I, Precioso D, Sierra MJ, Vegas-Azcárate S, Fernández Balbuena S, Vitoriano B, et al. Effectiveness of non-pharmaceutical interventions in nine fields of activity to decrease SARS-CoV-2 transmission (Spain, September 2020-May 2021). *Front Public Health*. 2023;11:1061331.
28. Adlhoch C, Delgado-Sanz C, Carnahan A, Larrauri A, Popovici O, Bossuyt N, et al. Effect of neuraminidase inhibitor (oseltamivir) treatment on outcome of hospitalised influenza patients, surveillance data from 11 EU countries, 2010 to 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2023 Jan;28(4).
29. Mazagatos C, Delgado-Sanz C, Milagro A, Liébana-Rodríguez M, Larrauri A. Impact of Influenza Vaccination on the Burden of Severe Influenza in the Elderly: Spain, 2017-2020. *Vaccines*. 2023 Jun 17;11(6).

## Año 2022

30. Sentís A, Kislaya I, Nicolay N, Meijerink H, Starrfelt J, Martínez-Baz I, et al. Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged  $\geq 65$  years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2022 Jul;27(30).
31. Schmidt SSS, Iuliano AD, Vestergaard LS, Mazagatos-Ateca C, Larrauri A, Brauner JM, et al. All-cause versus cause-specific excess deaths for estimating influenza-associated mortality in Denmark, Spain, and the United States. *Influenza Other Respir Viruses*. 2022 Jul;16(4):707–16.

32. Sandmann FG, van Leeuwen E, Bernard-Stoecklin S, Casado I, Castilla J, Domegan L, et al. Health and economic impact of seasonal influenza mass vaccination strategies in European settings: A mathematical modelling and cost-effectiveness analysis. *Vaccine*. 2022 Feb 23;40(9):1306–15.
33. Monge S, Rojas-Benedicto A, Olmedo C, Mazagatos C, José Sierra M, Limia A, et al. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study. *Lancet Infect Dis*. 2022 Sep;22(9):1313–20.
34. Monge S, Mazagatos C, Olmedo C, Rojas-Benedicto A, Simón F, Vega-Piris L, et al. [Effectiveness of vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty/fifty-nine.]. *Rev Esp Salud Publica*. 2022 Sep 2;96:e202209060.
35. Mazagatos C, Delgado-Sanz C, Monge S, Pozo F, Oliva J, Sandonis V, et al. COVID-19 vaccine effectiveness against hospitalization due to SARS-CoV-2: A test-negative design study based on Severe Acute Respiratory Infection (SARI) sentinel surveillance in Spain. *Influenza Other Respir Viruses*. 2022 Nov;16(6):1014–25.
36. Konstantinoudis G, Cameletti M, Gómez-Rubio V, Gómez IL, Pirani M, Baio G, et al. Regional excess mortality during the 2020 COVID-19 pandemic in five European countries. *Nat Commun*. 2022 Jan 25;13(1):482.
37. Kissling E, Hooiveld M, Martínez-Baz I, Mazagatos C, William N, Vilcu AM, et al. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2022 May;27(21).
38. García-García D, Herranz-Hernández R, Rojas-Benedicto A, León-Gómez I, Larrauri A, Peñuelas M, et al. Assessing the effect of non-pharmaceutical interventions on COVID-19 transmission in Spain, 30 August 2020 to 31 January 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2022 May;27(19).
39. De Salazar PM, Lu F, Hay JA, Gómez-Barroso D, Fernández-Navarro P, Martínez EV, et al. Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data. *PLoS Comput Biol*. 2022 Mar;18(3):e1009964.
40. Bagaria J, Jansen T, Marques DF, Hooiveld M, McMenamin J, de Lusignan S, et al. Rapidly adapting primary care sentinel surveillance across seven countries in Europe for COVID-19 in the first half of 2020: strengths, challenges, and lessons learned. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2022 Jun;27(26).
41. Armero G, Penela-Sánchez D, Belmonte J, Gómez-Barroso D, Larrauri A, Henares D, et al. Concentrations of nitrogen compounds are related to severe rhinovirus infection in infants. A time-series analysis from the reference area of a pediatric university hospital in Barcelona. *Pediatr Pulmonol*. 2022 Sep;57(9):2180–8.

## Año 2021

42. Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. The Global Epidemiology of RSV in Community and Hospitalized Care: Findings From 15 Countries. *Open Forum Infect Dis*. 2021 Jul;8(7):ofab159.

43. Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. *Influenza Other Respir Viruses*. 2021 Nov;15(6):732–41.
44. Rosillo N, Del-Águila-Mejía J, Rojas-Benedicto A, Guerrero-Vadillo M, Peñuelas M, Mazagatos C, et al. Real time surveillance of COVID-19 space and time clusters during the summer 2020 in Spain. *BMC Public Health*. 2021 May 21;21(1):961.
45. Nørgaard SK, Vestergaard LS, Nielsen J, Richter L, Schmid D, Bustos N, et al. Real-time monitoring shows substantial excess all-cause mortality during second wave of COVID-19 in Europe, October to December 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2021 Jan;26(2).
46. Mortier P, Vilagut G, Ferrer M, Alayo I, Bruffaerts R, Cristóbal-Narváez P, et al. Thirty-day suicidal thoughts and behaviours in the Spanish adult general population during the first wave of the Spain COVID-19 pandemic. *Epidemiol Psychiatr Sci*. 2021 Feb 17;30:e19.
47. Monge S, Olmedo C, Alejos B, Lapeña MF, Sierra MJ, Limia A. Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain. *Emerg Infect Dis*. 2021 Oct;27(10):2595–603.
48. Meslé MM, Brown J, Mook P, Hagan J, Pastore R, Bundle N, et al. Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region, December 2020 to November 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2021 Nov;26(47).
49. Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E, et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2021 Jun;26(24).
50. Mazagatos C, Monge S, Olmedo C, Vega L, Gallego P, Martín-Merino E, et al. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2021 Jun;26(24).
51. Machado A, Leite A, Larrauri A, Gomez V, Rodrigues AP, Kislaya I, et al. No effect modification of influenza virus vaccine effectiveness by age or chronic condition was observed in the 2010/11 to 2017/18 seasons. *Pharmacoepidemiol Drug Saf*. 2021 Oct;30(10):1411–9.
52. León-Gómez I, Mazagatos C, Delgado-Sanz C, Frías L, Vega-Piris L, Rojas-Benedicto A, et al. The Impact of COVID-19 on Mortality in Spain: Monitoring Excess Mortality (MoMo) and the Surveillance of Confirmed COVID-19 Deaths. *Viruses*. 2021 Dec 3;13(12).
53. Larrauri A, Prosenc Trilar K. Preparing for an influenza season 2021/22 with a likely co-circulation of influenza virus and SARS-CoV-2. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2021 Oct;26(41).
54. Kissling E, Hooiveld M, Sandonis Martín V, Martínez-Baz I, William N, Vilcu AM, et al. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2021 Jul;26(29).

55. Adlhoch C, Sneiderman M, Martinuka O, Melidou A, Bundle N, Fielding J, et al. Spotlight influenza: The 2019/20 influenza season and the impact of COVID-19 on influenza surveillance in the WHO European Region. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2021 Oct;26(40).

## Año 2020

56. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020 Dec;25(50).
57. Vestergaard LS, Nielsen J, Richter L, Schmid D, Bustos N, Braeye T, et al. Excess all-cause mortality during the COVID-19 pandemic in Europe - preliminary pooled estimates from the EuroMOMO network, March to April 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020 Jul;25(26).
58. Spiteri G, Fielding J, Diercke M, Campese C, Enouf V, Gaymard A, et al. First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020 Mar;25(9).
59. Singh DE, Marinescu MC, Carretero J, Delgado-Sanz C, Gomez-Barroso D, Larrauri A. Evaluating the impact of the weather conditions on the influenza propagation. *BMC Infect Dis.* 2020 Apr 5;20(1):265.
60. Rose AMC, Kissling E, Gherasim A, Casado I, Bella A, Launay O, et al. Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine. *Influenza Other Respir Viruses.* 2020 May;14(3):302-10.
61. Rose A, Kissling E, Emborg HD, Larrauri A, McMenamin J, Pozo F, et al. Interim 2019/20 influenza vaccine effectiveness: six European studies, September 2019 to January 2020. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020 Mar;25(10).
62. Redondo-Bravo L, Delgado-Sanz C, Oliva J, Vega T, Lozano J, Larrauri A. Transmissibility of influenza during the 21st-century epidemics, Spain, influenza seasons 2001/02 to 2017/18. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2020 May;25(21).
63. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo-Iglesias J, et al. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. *BMJ.* 2020 Nov 27;371:m4509.
64. Mook P, Meerhoff T, Olsen SJ, Snacken R, Adlhoch C, Pereyaslov D, et al. Alternating patterns of seasonal influenza activity in the WHO European Region following the 2009 pandemic, 2010-2018. *Influenza Other Respir Viruses.* 2020 Mar;14(2):150-61.
65. Mazagatos C, Godoy P, Muñoz Almagro C, Pozo F, Larrauri A. Effectiveness of influenza vaccination during pregnancy to prevent severe infection in children under 6 months of age, Spain, 2017-2019. *Vaccine.* 2020 Dec 14;38(52):8405-10.
66. Machado A, Santos AJ, Kislaya I, Larrauri A, Nunes B. Understanding influenza vaccination among Portuguese elderly: the social ecological framework. *Health Promot Int.* 2020 Dec 1;35(6):1427-40.



67. Delgado-Sanz C, Mazagatos-Ateca C, Oliva J, Gherasim A, Larrauri A. Illness Severity in Hospitalized Influenza Patients by Virus Type and Subtype, Spain, 2010-2017. *Emerg Infect Dis.* 2020 Feb;26(2):220–8.
68. De Salazar PM, Gómez-Barroso D, Pampaka D, Gil JM, Peñalver B, Fernández-Escobar C, et al. Lockdown measures and relative changes in the age-specific incidence of SARS-CoV-2 in Spain. *Epidemiol Infect.* 2020 Oct 21;148:e268.
69. Brugueras S, Fernández-Martínez B, Martínez-de la Puente J, Figuerola J, Porro TM, Rius C, et al. Environmental drivers, climate change and emergent diseases transmitted by mosquitoes and their vectors in southern Europe: A systematic review. *Environ Res.* 2020 Dec;191:110038.

## Año 2019

70. Segaloff H, Melidou A, Adlhoch C, Pereyaslov D, Robesyn E, Penttinen P, et al. Co-circulation of influenza A(H1N1)pdm09 and influenza A(H3N2) viruses, World Health Organization (WHO) European Region, October 2018 to February 2019. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2019 Feb;24(9).
71. Nielsen J, Vestergaard LS, Richter L, Schmid D, Bustos N, Asikainen T, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? *Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis.* 2019 Oct;25(10):1266–76.
72. Machado A, Mazagatos C, Dijkstra F, Kislaya I, Gherasim A, McDonald SA, et al. Impact of influenza vaccination programmes among the elderly population on primary care, Portugal, Spain and the Netherlands: 2015/16 to 2017/18 influenza seasons. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2019 Nov;24(45).
73. Machado A, Kislaya I, Larrauri A, Matias Dias C, Nunes B. Impact of national influenza vaccination strategy in severe influenza outcomes among the high-risk Portuguese population. *BMC Public Health.* 2019 Dec 16;19(1):1690.
74. Kissling E, Rose A, Emborg HD, Gherasim A, Pebody R, Pozo F, et al. Interim 2018/19 influenza vaccine effectiveness: six European studies, October 2018 to January 2019. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2019 Feb;24(8).
75. Kissling E, Pozo F, Buda S, Vilcu AM, Gherasim A, Brytting M, et al. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15-64-year-olds in Europe: exploration by birth cohort. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2019 Nov;24(48).
76. Kissling E, Pozo F, Buda S, Vilcu AM, Rizzo C, Gherasim A, et al. Effectiveness of influenza vaccine against influenza A in Europe in seasons of different A(H1N1)pdm09 and the same A(H3N2) vaccine components (2016-17 and 2017-18). *Vaccine X.* 2019 Dec 10;3:100042.
77. Brotons P, Nogueras MM, Valls A, Larrauri A, Dominguez A, Launes C, et al. Impact of Rapid On-demand Molecular Diagnosis of Pediatric Seasonal Influenza on Laboratory Workflow and Testing Costs: A Retrospective Study. *Pediatr Infect Dis J.* 2019 Jun;38(6):559–63.
78. Adlhoch C, Gomes Dias J, Bonmarin I, Hubert B, Larrauri A, Oliva Domínguez JA, et al. Determinants of Fatal Outcome in Patients Admitted to Intensive Care Units With Influenza, European Union 2009-2017. *Open Forum Infect Dis.* 2019 Nov;6(11):ofz462.

## Año 2018

79. Valenciano M, Kissling E, Larrauri A, Nunes B, Pitigoi D, O'Donnell J, et al. Exploring the effect of previous inactivated influenza vaccination on seasonal influenza vaccine effectiveness against medically attended influenza: Results of the European I-MOVE multicentre test-negative case-control study, 2011/2012-2016/2017. *Influenza Other Respir Viruses*. 2018 Sep;12(5):567–81.
80. Rondy M, Kissling E, Emborg HD, Gherasim A, Pebody R, Trebbien R, et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2018 Mar;23(9).
81. Oliva J, Delgado-Sanz C, Larrauri A. Estimating the burden of seasonal influenza in Spain from surveillance of mild and severe influenza disease, 2010-2016. *Influenza Other Respir Viruses*. 2018 Jan;12(1):161–70.
82. Mazagatos C, Delgado-Sanz C, Oliva J, Gherasim A, Larrauri A. Exploring the risk of severe outcomes and the role of seasonal influenza vaccination in pregnant women hospitalized with confirmed influenza, Spain, 2010/11-2015/16. *PLoS One*. 2018;13(8):e0200934.
83. Kissling E, Valenciano M, Pozo F, Vilcu AM, Reuss A, Rizzo C, et al. 2015/16 I-MOVE/I-MOVE+ multicentre case-control study in Europe: Moderate vaccine effectiveness estimates against influenza A(H1N1)pdm09 and low estimates against lineage-mismatched influenza B among children. *Influenza Other Respir Viruses*. 2018 Jul;12(4):423–37.
84. Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. *Lancet Lond Engl*. 2018 Mar 31;391(10127):1285–300.

## Año 2017

85. Vestergaard LS, Nielsen J, Krause TG, Espenhain L, Tersago K, Bustos Sierra N, et al. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2017 Apr 6;22(14):30506.
86. Rondy M, Launay O, Castilla J, Costanzo S, Puig-Barberà J, Gefenaite G, et al. Repeated seasonal influenza vaccination among elderly in Europe: Effects on laboratory confirmed hospitalised influenza. *Vaccine*. 2017 Aug 3;35(34):4298–306.
87. Rondy M, Larrauri A, Casado I, Alfonsi V, Pitigoi D, Launay O, et al. 2015/16 seasonal vaccine effectiveness against hospitalisation with influenza A(H1N1)pdm09 and B among elderly people in Europe: results from the I-MOVE+ project. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2017 Jul 27;22(30):30580.
88. Rondy M, Gherasim A, Casado I, Launay O, Rizzo C, Pitigoi D, et al. Low 2016/17 season vaccine effectiveness against hospitalised influenza A(H3N2) among elderly: awareness warranted for 2017/18 season. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2017 Oct;22(41).
89. Kissling E, Rondy M. Early 2016/17 vaccine effectiveness estimates against influenza A(H3N2): I-MOVE multicentre case control studies at primary care and hospital levels in Europe. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2017 Feb 16;22(7):30464.



90. Gomez-Barroso D, León-Gómez I, Delgado-Sanz C, Larrauri A. Climatic Factors and Influenza Transmission, Spain, 2010-2015. *Int J Environ Res Public Health*. 2017 Nov 28;14(12).
91. Gherasim A, Martínez-Baz I, Castilla J, Pozo F, Larrauri A. Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain. *PloS One*. 2017;12(6):e0179160.
92. Bangert M, Gil H, Oliva J, Delgado C, Vega T, DE Mateo S, et al. Pilot study to harmonize the reported influenza intensity levels within the Spanish Influenza Sentinel Surveillance System (SISS) using the Moving Epidemic Method (MEM). *Epidemiol Infect*. 2017 Mar;145(4):715–22.

### Año 2016

93. Valenciano M, Kissling E, Reuss A, Rizzo C, Gherasim A, Horváth JK, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in primary care patients in a season of co-circulation of influenza A(H1N1)pdm09, B and drifted A(H3N2), I-MOVE Multicentre Case-Control Study, Europe 2014/15. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2016;21(7):pii=30139.
94. Kissling E, Nunes B, Robertson C, Valenciano M, Reuss A, Larrauri A, et al. I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2016 Apr 21;21(16).
95. Jiménez-Jorge S, Delgado-Sanz C, de Mateo S, Pozo F, Casas I, Larrauri A. [Monitoring respiratory syncytial virus through the Spanish influenza surveillance system, 2006-2014]. *Enferm Infecc Microbiol Clin*. 2016 Feb;34(2):117–20.
96. Gherasim A, Pozo F, de Mateo S, Gamarra IA, García-Cenoz M, Vega T, et al. Waning protection of influenza vaccine against mild laboratory confirmed influenza A(H3N2) and B in Spain, season 2014-15. *Vaccine*. 2016 Apr 29;34(20):2371–7.
97. Broberg E, Melidou A, Prosenc K, Bragstad K, Hungnes O. Predominance of influenza A(H1N1)pdm09 virus genetic subclade 6B.1 and influenza B/Victoria lineage viruses at the start of the 2015/16 influenza season in Europe. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2016;21(13).

### Año 2015

98. Vega T, Lozano JE, Meerhoff T, Snacken R, Beauté J, Jorgensen P, et al. Influenza surveillance in Europe: comparing intensity levels calculated using the moving epidemic method. *Influenza Other Respir Viruses*. 2015 Sep;9(5):234–46.
99. Valenciano M, Kissling E, Reuss A, Jiménez-Jorge S, Horváth JK, Donnell JMO, et al. The European I-MOVE Multicentre 2013-2014 Case-Control Study. Homogeneous moderate influenza vaccine effectiveness against A(H1N1)pdm09 and heterogeneous results by country against A(H3N2). *Vaccine*. 2015 Jun 4;33(24):2813–22.
100. Molbak K, Espenhain L, Nielsen J, Tersago K, Bossuyt N, Denissov G, et al. Excess mortality among the elderly in European countries, December 2014 to February 2015. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2015 Mar 19;20(11):21065.

101. León-Gómez I, Delgado-Sanz C, Jiménez-Jorge S, Flores V, Simón F, Gómez-Barroso D, et al. [Excess mortality associated with influenza in Spain in winter 2012]. *Gac Sanit.* 2015 Aug;29(4):258–65.
102. Jiménez-Jorge S, Pozo F, Larrauri A. Interim influenza vaccine effectiveness: A good proxy for final estimates in Spain in the seasons 2010-2014. *Vaccine.* 2015 Jun 26;33(29):3276–80.
103. Jimenez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Estimating influenza vaccine effectiveness in Spain using sentinel surveillance data. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2015 Jul 16;20(28):21187.
104. Broberg E, Snacken R, Adlhoch C, Beauté J, Galinska M, Pereyaslov D, et al. Start of the 2014/15 influenza season in Europe: drifted influenza A(H3N2) viruses circulate as dominant subtype. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2015 Jan 29;20(4):21023.
105. Beauté J, Zucs P, Korsun N, Bragstad K, Enouf V, Kossyvakis A, et al. Age-specific differences in influenza virus type and subtype distribution in the 2012/2013 season in 12 European countries. *Epidemiol Infect.* 2015 Oct;143(14):2950–8.

#### Año 2014

106. Gomez-Barroso D, Martinez-Beneito MA, Flores V, Amorós R, Delgado C, Botella P, et al. Geographical spread of influenza incidence in Spain during the 2009 A(H1N1) pandemic wave and the two succeeding influenza seasons. *Epidemiol Infect.* 2014 Dec;142(12):2629–41.
107. Jimenez-Jorge S, Pozo F, de Mateo S, Delgado-Sanz C, Casas I, Garcia-Cenoz M, et al. Influenza vaccine effectiveness in Spain 2013/14: subtype-specific early estimates using the cycEVA study. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2014 Mar 6;19(9):20727.
108. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, et al. Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2014 Feb 13;19(6):20701.
109. Savulescu C, Jiménez-Jorge S, Delgado-Sanz C, de Mateo S, Pozo F, Casas I, et al. Higher vaccine effectiveness in seasons with predominant circulation of seasonal influenza A(H1N1) than in A(H3N2) seasons: test-negative case-control studies using surveillance data, Spain, 2003-2011. *Vaccine.* 2014 Jul 31;32(35):4404–11.

#### Año 2013

110. Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. *BMC Infect Dis.* 2013 Sep 22;13:441.
111. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2013 Jan 31;18(5):20390.

112. Simonsen L, Spreeuwenberg P, Lustig R, Taylor RJ, Fleming DM, Kroneman M, et al. Global mortality estimates for the 2009 Influenza Pandemic from the GLaMOR project: a modeling study. *PLoS Med.* 2013 Nov;10(11):e1001558.
113. Valenciano M, Kissling E. Early estimates of seasonal influenza vaccine effectiveness in Europe: results from the I-MOVE multicentre case-control study, 2012/13. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2013 Feb 14;18(7):3.

## Año 2012

114. Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, Garcia Cenoz M, Castilla J, et al. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2012 Mar 22;17(12):20129.
115. Jiménez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, et al. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. *Vaccine.* 2012 May 21;30(24):3595–602.
116. Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe among target groups for vaccination: results from the I-MOVE multicentre case-control study, 2011/12. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2012 Apr 12;17(15):20146.
117. Ledesma J, Pozo F, Reina G, Blasco M, Rodríguez G, Montes M, et al. Genetic diversity of influenza A(H1N1)2009 virus circulating during the season 2010-2011 in Spain. *J Clin Virol Off Publ Pan Am Soc Clin Virol.* 2012 Jan;53(1):16–21.
118. López-Cuadrado T, de Mateo S, Jiménez-Jorge S, Savulescu C, Larrauri A. Influenza-related mortality in Spain, 1999-2005. *Gac Sanit.* 2012 Aug;26(4):325–9.
119. Martirosyan L, Paget WJ, Jorgensen P, Brown CS, Meerhoff TJ, Pereyaslov D, et al. The community impact of the 2009 influenza pandemic in the WHO European region: a comparison with historical seasonal data from 28 countries. *BMC Infect Dis.* 2012 Feb 10;12:36.
120. Valenciano M, Ciancio B. I-MOVE: a European network to measure the effectiveness of influenza vaccines. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2012 Sep 27;17(39):20281.

## Año 2011

121. Amato-Gauci A, Zucs P, Snacken R, Ciancio B, Lopez V, Broberg E, et al. Surveillance trends of the 2009 influenza A(H1N1) pandemic in Europe. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2011 Jun 30;16(26):19903.
122. Godoy P, Pumarola T, Sierra MJ, Godoy P, Torner N, Calafell F, et al. [Conclusions of the workshop 'Results and lessons learned during the pandemic flu (H1N1) 2009 from the research and the public health surveillance']. *Rev Esp Salud Publica.* 2011 Feb;85(1):121–2.
123. Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull.* 2011 Mar 17;16(11):19818.

124. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, et al. I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. *PloS One*. 2011;6(11):e27622.
125. Larrauri A, Savulescu C, Jiménez-Jorge S, Pérez-Breña P, Pozo F, Casas I, et al. Influenza pandemic (H1N1) 2009 activity during summer 2009. Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain. *Gac Sanit*. 2011 Feb;25(1):23–8.
126. Ledesma J, Pozo F, Pérez Ruiz M, Navarro JM, Piñeiro L, Montes M, et al. Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2011 May;51(1):75–8.
127. Ledesma J, Vicente D, Pozo F, Cilla G, Castro SP, Fernández JS, et al. Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain. *J Clin Virol Off Publ Pan Am Soc Clin Virol*. 2011 Jul;51(3):205–8.
128. Savulescu C, Jiménez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2011 Mar 17;16(11):19820.

## Año 2010

129. Savulescu C, Jiménez-Jorge S, de Mateo S, Pozo F, Casas I, Breña PP, et al. Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010. *BMC Public Health*. 2011 Nov 30;11:899.
130. Devaux I, Kreidl P, Penttinen P, Salminen M, Zucs P, Ammon A. Initial surveillance of 2009 influenza A(H1N1) pandemic in the European Union and European Economic Area, April-September 2009. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2010 Dec 9;15(49):19740.
131. Mereckiene J, Cotter S, D’Ancona F, Giambi C, Nicoll A, Levy-Bruhl D, et al. Differences in national influenza vaccination policies across the European Union, Norway and Iceland 2008-2009. *Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull*. 2010 Nov 4;15(44):19700.
132. Paget WJ, Balderston C, Casas I, Donker G, Edelman L, Fleming D, et al. Assessing the burden of paediatric influenza in Europe: the European Paediatric Influenza Analysis (EPIA) project. *Eur J Pediatr*. 2010 Aug;169(8):997–1008.
133. Savulescu C, Valenciano M, de Mateo S, Larrauri A. Estimating the influenza vaccine effectiveness in elderly on a yearly basis using the Spanish influenza surveillance network--pilot case-control studies using different control groups, 2008-2009 season, Spain. *Vaccine*. 2010 Apr 1;28(16):2903–7.